Endocyte (ECYT) Shares Jump as Co. Seeking EU Approval for Ovarian Cancer Treatment; AEterna Zentaris (AEZS) Also Higher
Tweet
Share
E-mailGet Alerts ECYT Hot Sheet
Join SI Premium – FREE
Shares of Endocyte (Nasdaq: ECYT) surged sharply Tuesday following news the company is looking to receive EU approval for its EC145 candidate and its companion imaging diagnostic EC20.
The stock is now up nearly 26 percent to $11.94.
Elsewhere in the Biotech and Drug sector, shares of AEterna Zentaris (Nasdaq: AEZS) are up about 7 percent amid the Endocyte news.
The stock is now up nearly 26 percent to $11.94.
Elsewhere in the Biotech and Drug sector, shares of AEterna Zentaris (Nasdaq: AEZS) are up about 7 percent amid the Endocyte news.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Sky Quarry names Heidi Bowman as CFO
- Adient amends credit deal, adds $500M in incremental term loans
Create E-mail Alert Related Categories
Corporate News, FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
